Wave Life Sciences (WVE) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)

Wave Life Sciences (WVE) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 45.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 91.31%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Wave Life Sciences 1.19 Bn 649.41 Mn - 1.63%

Historic Data

Download Data
DateValue
Mar 31, 2026 1.63%
Dec 31, 2025 -6.76%
Sep 30, 2025 -11.35%
Jun 30, 2025 -6.92%
Mar 31, 2025 -7.43%
Dec 31, 2024 41.63%
Sep 30, 2024 -114.84%
Jun 30, 2024 5.30%
Mar 31, 2024 9.42%
Dec 31, 2023 17.31%
Sep 30, 2023 30.43%
Jun 30, 2023 19.55%
Mar 31, 2023 16.75%
Dec 31, 2022 8.35%
Sep 30, 2022 8.39%
Jun 30, 2022 0.52%
Mar 31, 2022 5.07%
Dec 31, 2021 2.78%
Sep 30, 2021 45.09%
Jun 30, 2021 -2.60%